On the possible increase in local tumour control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule

W A Tomé; S P Howard
January 2007
British Journal of Radiology;Jan2007, Vol. 80 Issue 949, p32
Academic Journal
Using modelling, we have developed a treatment strategy for gliomas exhibiting low dose hyper-radiosensitivity (HRS) that employs both a reduced dose-rate and pulsed treatment dose delivery. The model exploits the low dose hypersensitivity observed in some glioma cell lines at low radiation doses. We show, based on in vitro data, that a pulsed delivery of external beam radiation therapy could yield significant increases in local control. We therefore propose a pulsed delivery scheme for the treatment of gliomas in which the daily treatment fraction is delivered using 0.20 Gy pulses, separated by three minutes for a time-averaged dose-rate of 0.0667 Gy/min. The dose per pulse of 0.2 Gy is near or below the transition dose observed in vitro for four of the five glioma cell lines we have studied. Using five established glioma cell lines our modelling demonstrates that our pulsed delivery scheme yields a substantial increase in tumour control probability (TCP).


Related Articles

  • Disentangling Gliomas. Breindl, Anette // BioWorld Today;4/4/2011, Vol. 22 Issue 64, Special section p1 

    The article focuses on a study by researchers from the University of Alabama at Birmingham which discovered a way to prevent gliomas from growing.

  • Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response. Pei-Ming Chu; Shih-Hwa Chiou; Tsann-Long Su; Yi-Jang Lee; Li-Hsin Chen; Yi-Wei Chen; Sang-Hue Yen; Ming-Teh Chen; Ming-Hsiung Chen; Yang-Hsin Shih; Pang-Hsien Tu; Hsin-I. Ma // Radiation Oncology;2011, Vol. 6 Issue 1, p7 

    Background: 1-{4-[Bis(2-chloroethyl)amino]phenyl}-3-[2-methyl-5-(4-methylacridin-9-ylamino)phenyl]urea (BO-1051) is an N-mustard DNA alkylating agent reported to exhibit antitumor activity. Here we further investigate the effects of this compound on radiation responses of human gliomas, which...

  • Inhibition of Neovascularization and Tumor Growth, and Facilitation of Wound Repair, by Halofuginone, an Inhibitor of Collagen Type I Synthesis. Abramovitch, Rinat; Dafni, Hagit; Neeman, Michal; Nagler, Arnon; Pines, Mark // Neoplasia;Oct99, Vol. 1 Issue 4, p321 

    Halofuginone, an inhibitor of collagen a1(I) gene expression was used for the treatment of subcutaneously implanted C6 glioma tumors. Halofuginone had no effect on the growth of C6 glioma spheroids in vitro, and these spheroids showed no collagen a1(I) expression and no collagen synthesis....

  • Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Harada, H.; Itasaka, S.; Zhu, Y.; Zeng, L.; Xie, X.; Morinibu, A.; Shinomiya, K.; Hiraoka, M. // British Journal of Cancer;3/10/2009, Vol. 100 Issue 5, p747 

    Hypoxia-inducible factor-1 (HIF-1) has been reported to promote tumour radioresistance; therefore, it is recognised as an excellent target during radiation therapy. However, the inhibition of HIF-1 in unsuitable timing can suppress rather than enhance the effect of radiation therapy because its...

  • The confluence of radiotherapy and immunotherapy. Burnette, Byron; Yang-Xin Fu; Weichselbaum, Ralph R. // Frontiers in Oncology;Oct2012, Vol. 2, p1 

    Radiotherapy (RT) has been considered a local modality and outcomes have emphasized local and regional control of tumors. Recent data suggests that RT may activate the immune system and the combination of radiation therapy and immune therapies may have the potential to improve both local and...

  • Inhibition of Hec1 as a novel approach for treatment of primary liver cancer. Huang, Lynn; Chang, Chia-chi; Lee, Ying-Shuan; Huang, Jiann-Jyh; Chuang, Shih-Hsien; Chang, Jia-Ming; Kao, Kuo-Jang; Lau, Gillian; Tsai, Pei-Yi; Liu, Chia-wei; Lin, Her-Sheng; Gish, Robert; Lau, Johnson // Cancer Chemotherapy & Pharmacology;Sep2014, Vol. 74 Issue 3, p511 

    Purpose: Highly expressed in cancer protein 1 (Hec1) is an oncogene and a promising molecular target for novel anticancer drugs. The purpose of this study was to evaluate the potential of a Hec1 inhibitor, TAI-95, as a treatment for primary liver cancer. Methods: In vitro and in vivo methods...

  • MicroRNA-217 Regulates WASF3 Expression and Suppresses Tumor Growth and Metastasis in Osteosarcoma. Shen, Lei; Wang, Peng; Yang, Jili; Li, Xiaotao // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Osteosarcoma is the most common type of primary tumor of bone which mainly affects adolescents and young adults. Osteosarcoma causes large number of deaths because of its complex pathogenesis and resistance to conventional treatment. MicroRNAs are a class of small noncoding RNAs that function as...

  • Triptolide inhibits proliferation and invasion of malignant glioma cells. Zhang, Haipeng; Zhu, Wenbo; Su, Xingwen; Wu, Sihan; Lin, Yuan; Li, Jingjie; Wang, Youqiong; Chen, Jingkao; Zhou, Yuxi; Qiu, Pengxin; Yan, Guangmei; Zhao, Shujin; Hu, Jun; Zhang, Jingxia // Journal of Neuro-Oncology;Aug2012, Vol. 109 Issue 1, p53 

    Malignant glioma is the most devastating and aggressive tumor in brain, characterized by rapid proliferation and diffuse invasion. Chemotherapy and radiotherapy are the pivotal strategies after surgery; however, high drug resistance of malignant glioma and the blood-brain barrier usually render...

  • Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation. Charest, Gabriel; Paquette, Benoit; Fortin, David; Mathieu, David; Sanche, Léon // Journal of Neuro-Oncology;Apr2010, Vol. 97 Issue 2, p187 

    Despite significant advances, the radiotherapy and chemotherapy protocols marginally improve the overall survival of patients with glioblastoma. LipoplatinTM, and LipoxalTM, the liposomal formulations of cisplatin and oxaliplatin respectively, were tested on the F98 glioma cells for their...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics